Provided by Tiger Trade Technology Pte. Ltd.

Protagonist Therapeutics

146.12
-1.6350-1.11%
Volume:103.47K
Turnover:15.15M
Market Cap:9.45B
PE:141.86
High:150.00
Open:147.75
Low:144.73
Close:147.75
52wk High:160.81
52wk Low:54.50
Shares:64.71M
Float Shares:63.17M
Volume Ratio:0.51
T/O Rate:0.16%
Dividend:- -
Dividend Rate:- -
EPS(TTM):1.03
EPS(LYR):-2.0500
ROE:10.98%
ROA:4.55%
PB:11.24
PE(LYR):-71.28

Loading ...

Analysts Conflicted on These Healthcare Names: Molina Healthcare (MOH), Design Therapeutics (DSGN) and Protagonist Therapeutics (PTGX)

TIPRANKS
·
Apr 29

Protagonist Therapeutics announces annual shareholder meeting via online webcast

Reuters
·
Apr 29

Protagonist Therapeutics Opts Out of Rusfertide US Profit-Sharing Arrangement With Takeda Pharmaceutical

MT Newswires Live
·
Apr 28

Protagonist exercises right to opt out of 50:50 U.S. arrangement for rusfertide

TIPRANKS
·
Apr 28

High Growth Tech Stocks To Watch In US April 2026

Simply Wall St.
·
Apr 25

Protagonist Therapeutics Insider Move: CFO Cashes In on a Notable Stock Sale

TIPRANKS
·
Apr 22

Protagonist Therapeutics grants inducement awards for 55,425 stock options, 14,425 RSUs

Reuters
·
Apr 17

Protagonist Therapeutics Is Maintained at Buy by Truist Securities

Dow Jones
·
Apr 15

Truist Raises Price Target on Protagonist Therapeutics to $121 From $110, Keeps Buy Rating

MT Newswires Live
·
Apr 15

Protagonist Therapeutics: Icotyde’s Rapid Psoriasis Uptake and Multibillion‑Dollar Peak Sales Potential Support Buy Rating and Higher $121 Target

TIPRANKS
·
Apr 15

Protagonist Therapeutics price target raised to $121 from $110 at Truist

TIPRANKS
·
Apr 15

J&J raises guidance for 2026 on strong start to the year

Dow Jones
·
Apr 14

Protagonist Therapeutics Inc : Clear Street Raises Target Price to $116 From $104

THOMSON REUTERS
·
Apr 07

Protagonist Therapeutics Is Maintained at Buy by Clear Street

Dow Jones
·
Apr 07

Protagonist Therapeutics price target raised to $116 from $104 at Clear Street

TIPRANKS
·
Apr 07

Assessing Protagonist Therapeutics (PTGX) Valuation After Strong 1‑Year Shareholder Return

Simply Wall St.
·
Mar 29

Protagonist says ICOTYDE Phase 3 one-year psoriasis data show durable skin clearance

Reuters
·
Mar 28

Protagonist Therapeutics Executives Quietly Cash In on Major Insider Stock Sales

TIPRANKS
·
Mar 28

J&J Exits 3 Biotechs, Retains Stakes in 2 Possible Acquisitions -- Barron's

Dow Jones
·
Mar 28

Protagonist Therapeutics; Chief Medical Officer Arturo Molina disposes of 15,000 common shares valued at $1,572,000

Reuters
·
Mar 28